



# Samrat Pharmachem Limited

Manufacturers, Importers & Exporters of Pharmaceutical Chemicals

Regd Office : Plot No. A2/3445, GIDC Phase 4, Ankleshwar 393 002, Gujarat

Corp Office : A/7, Sai Prasad, 2nd Floor, Teli Gali Cross Lane, Andheri (E), Mumbai-400 069

## Statement of Standalone Unaudited Results for the Quarter ended 30 June, 2012

(Rupees in Lakhs)

Particulars	Quarter Ended 30-Jun-12 (Unaudited)	Quarter Ended 30-Jun-11 (Unaudited)	Quarter Ended 31-Mar-12 (Audited)	Year Ended 31-Mar-12 (Audited)
1 (a). Net Income from Sales / Services	1,778.28	1,841.39	1,559.31	6,954.31
(b). Other Operating Income	2.53	0.00	0.68	0.77
Total Income	1,780.81	1,841.39	1,559.99	6,955.08
2. Expenditure				
a) (Increase)/Decrease in Stock in Trade/WIP	102.36	(300.60)	18.22	(588.77)
b) Consumption of Raw Materials	1,575.42	1,486.77	1,562.56	6,497.48
c) Purchase of Traded Goods	0.00	0.00	0.00	0.00
d) Employee Costs	27.22	22.24	23.39	79.88
e) Depreciation	5.87	4.58	5.59	19.28
f) Other Expenditure				
(i) Manufacturing Expenses	27.09	36.05	44.62	172.16
(ii) Administration Expenses	17.07	22.34	21.76	80.66
(iii) Selling & Distribution Expenses	8.56	18.29	25.48	77.20
g) Total	1,763.59	1,289.67	1,701.62	6,337.89
3. Profit from Operations before Other Income, Interest and Exceptional Items	17.22	551.72	(141.63)	617.19
4. Other Income	3.64	2.62	10.04	24.31
5. Profit before Interest and Exceptional items	20.86	554.34	(131.59)	641.50
6. Interest	17.43	14.29	14.07	61.60
7. Profit after Interest but before Exceptional items	3.43	540.05	(145.66)	579.90
8. Exceptional Items	0.00	0.00	0.00	0.00
9. Profit / (Loss) from ordinary activities before tax	3.43	540.05	(145.66)	579.90
10. Tax expense (incl deferred tax)	1.75	135.65	18.28	202.17
11. Net Profit / (Loss) from ordinary activities after tax	1.68	404.40	(163.94)	377.73
12. Extraordinary Items (Net of tax expense)	0.00	0.00	0.00	0.00
13. Net Profit / (Loss) for the period	1.68	404.40	(163.94)	377.73
14. Paid-up Equity Share Capital (Face Value Rs.10)	308.97	308.97	308.97	308.97
15. Reserves excluding revaluation reserves	942.24	967.37	940.69	940.69
16. Earnings per share				
a) Basic and diluted EPS before extraordinary items for the period, year-to-date, previous year	0.05	13.09	(5.31)	12.23
b) Basic and diluted EPS after extraordinary items for the period, year-to-date, previous year	0.05	13.09	(5.31)	12.23
17. Public shareholding				
-- Number of shares	1,660,956	1,775,480	1,664,521	1,664,521
-- Percentage of shareholding	53.76	57.46	53.87	53.87
18. Promoters and promoter group shareholding**				
a) Pledged/ Encumbered				
-- Number of shares	0.00	0.00	0.00	0.00
-- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	0.00	0.00	0.00	0.00
-- Percentage of shares (as a % of the total share capital of the company)	0.00	0.00	0.00	0.00

b) Non-encumbered				
-- Number of shares	<b>1,428,744</b>	1,314,220	1,425,179	1,425,179
-- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	<b>100.00</b>	100.00	100.00	100.00
-- Percentage of shares (as a % of the total share capital of the company)	<b>46.24</b>	42.54	46.13	46.13

**Notes:**

1. The above results were reviewed by the Audit Committee of the Board of Directors.
2. The Statutory Auditors have carried out a limited review of the results for the quarter ended 30 June, 2012
3. The above figures are after accounting for a net foreign exchange loss of Rs. 141 Lakhs during the quarter.
4. The above unaudited results have been taken on record by the Board of Directors at its Meeting held on Tuesday, 14 August 2012 at the Corporate Office of the Company.
5. Information on investor complaints pursuant to clause 41 of the listing agreement for the quarter ended 30 June, 2012

Opening Balance as on	1/Apr/2012	0
Received during the quarter		0
Disposed of during the quarter		0
Closing Balance as on	30/Jun/2012	0

**By order of the Board of Directors  
For Samrat Pharmachem Limited**

**Place : Mumbai**  
**Date : 14 August 2012**

**Rajesh Mehta**  
**Executive Director**